HuGE Literature Finder
Records
1
-
30
| Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial. BMC cancer 2023 1 23 (1): 6. Miura Satoru, Koh Yasuhiro, Azuma Koichi, Yoshioka Hiroshige, Koyama Kenichi, Teraoka Shunsuke, Ishii Hidenobu, Kibata Kayoko, Ozawa Yuichi, Tokito Takaaki, Oyanagi Jun, Shimokawa Toshio, Kurata Takayasu, Yamamoto Nobuyuki, Tanaka Hiros |
| Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial. Lung cancer (Amsterdam, Netherlands) 2023 3 178 151-156. Lv Chao, Fang Wentao, Wu Nan, Jiao Wenjie, Xu Shidong, Ma Haitao, Wang Jia, Wang Rui, Ji Chunyu, Li Shaolei, Wang Yuzhao, Yan Shi, Lu Fangliang, Pei Yuquan, Liu Yinan, Yang Y |
| Pharmacokinetic and dose-finding study of osimertinib in patients with impaired renal function and low body weight. Cancer science 2023 1 . Fujiwara Yutaka, Makihara Reiko, Hase Tetsunari, Hashimoto Naozumi, Naito Tomoyuki, Tsubata Yukari, Okuno Takae, Takahashi Toshiaki, Kobayashi Haruki, Shinno Yuki, Zenke Yoshitaka, Ikeda Takaya, Hosomi Yukio, Watanabe Kageaki, Kitazono Satoru, Sakiyama Naomi, Makino Yoshinori, Yamamoto Nobo |
| Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study. Investigational new drugs 2023 1 . Ishikawa Emi, Yokoyama Yuta, Chishima Haruna, Kasai Hidefumi, Kuniyoshi Ouki, Kimura Motonori, Hakamata Jun, Nakada Hideo, Suehiro Naoya, Nakaya Naoki, Nakajima Hideo, Ikemura Shinnosuke, Kawada Ichiro, Yasuda Hiroyuki, Terai Hideki, Jibiki Aya, Kawazoe Hitoshi, Soejima Kenzo, Muramatsu Hiroshi, Suzuki Sayo, Nakamura Tomono |
| Side effects of tyrosine kinase inhibitors therapy in patients with non-small cell lung cancer and associations with EGFR polymorphisms: A systematic review and meta-analysis. Oncology letters 2023 1 25 (2): 62. Obradovic Jasmina, Todosijevic Jovana, Jurisic Vladim |
| Afatinib 30 mg in the treatment of common and uncommon EGFR-mutated advanced lung adenocarcinomas: a retrospective, single-center, longitudinal study. Journal of thoracic disease 2022 Jun 14 (6): 2169-2177. Qian Jie, Ye Xuanting, Huang Aimi, Qin Ruoyan, Cai Yuqing, Xue Yiqian, Zhang Shi, Wang Weimin, Xiong Liwen, Gu Aiq |
| Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B). Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Jun OF1-OF10. Yang James Chih-Hsin, Ohe Yuichiro, Chiu Chao-Hua, Ou Xiaoling, Cantarini Mireille, Jänne Pasi A, Hartmaier Ryan J, Ahn Myung |
| Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial. BMC medicine 2022 Feb 20 (1): 42. Song Zhengbo, Li Yuping, Chen Shiqing, Ying Shenpeng, Xu Shuguang, Huang Jianjin, Wu Dan, Lv Dongqing, Bei Ting, Liu Shuxun, Huang Xiaoping, Xie Congying, Wu Xiaoyu, Fu Jianfei, Hua Feng, Wang Wenxian, Xu Chunwei, Gao Chan, Cai Shangli, Lu Shun, Zhang Yipi |
| A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors. Lung cancer (Amsterdam, Netherlands) 2022 3 166 98-106. Lin Lin, Pan Hongming, Li Xingya, Zhao Chengling, Sun Jiangtao, Hu Xingsheng, Zhang Yiping, Wang Mengzhao, Ren Xiubao, Luo Xiaoyong, Shan Guoyong, Hui Ai-Min, Wu Zhuli, Liu Huilong, Tian Ling, Shi Yuank |
| AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 5 40 (27): 3162-3171. Lu Shun, Dong Xiaorong, Jian Hong, Chen Jianhua, Chen Gongyan, Sun Yuping, Ji Yinghua, Wang Ziping, Shi Jianhua, Lu Junguo, Chen Shaoshui, Lv Dongqing, Zhang Guojun, Liu Chunling, Li Juan, Yu Xinmin, Lin Zhong, Yu Zhuang, Wang Zhehai, Cui Jiuwei, Xu Xingxiang, Fang Jian, Feng Jifeng, Xu Zhi, Ma Rui, Hu Jie, Yang Nong, Zhou Xiangdong, Wu Xiaohong, Hu Chengping, Zhang Zhihong, Lu You, Hu Yanping, Jiang Liyan, Wang Qiming, Guo Renhua, Zhou Jianying, Li Baolan, Hu Chunhong, Tong Wancheng, Zhang Helong, Ma Lin, Chen Yuan, Jie Zhijun, Yao Yu, Zhang Longzhen, Jie Weng, Li Weidong, Xiong Jianping, Ye Xianwei, Duan Jianchun, Yang Haihua, Sun Meili, Sun Changan, Wei Hongying, Li Chuan, Ali Siraj M, Miller Vincent A, Wu Qio |
| Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L). Lung cancer (Amsterdam, Netherlands) 2022 4 168 38-45. Hayashi Hidetoshi, Yonesaka Kimio, Nakamura Atsushi, Fujimoto Daichi, Azuma Koichi, Sakata Shinya, Tachihara Motoko, Ikeda Satoshi, Yokoyama Toshihide, Hataji Osamu, Yano Yukihiro, Hirano Katsuya, Daga Haruko, Okada Hideaki, Chiba Yasutaka, Sakai Kazuko, Nishio Kazuto, Yamamoto Nobuyuki, Nakagawa Kazuhi |
| Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02). Thoracic cancer 2022 4 13 (10): 1471-1478. Tanaka Hisashi, Sakamoto Hiroaki, Akita Takahiro, Ohyanagi Fumiyoshi, Kawashima Yosuke, Tambo Yuichi, Tanimoto Azusa, Horiike Atsushi, Miyauchi Eisaku, Tsuchiya-Kawano Yuko, Yanagitani Noriko, Nishio Mako |
| Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study. Therapeutic advances in medical oncology 2022 7 14 17588359221113278. Lee Suey-Haur, Lin Yu-Ching, Chiu Li-Chung, Ju Jia-Shiuan, Tung Pi-Hung, Huang Allen Chung-Cheng, Li Shih-Hong, Fang Yueh-Fu, Chen Chih-Hung, Kuo Scott Chih-Hsi, Wang Chin-Chou, Yang Cheng-Ta, Hsu Ping-Ch |
| Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials. BMC cancer 2022 3 22 (1): 328. Zhao Pengfei, Zhen Hongchao, Zhao Hong, Zhao Lei, Cao Bangw |
| Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies. Acta oncologica (Stockholm, Sweden) 2022 10 61 (11): 1347-1353. Li Li, Huang Qin, Sun Jianhai, Yan Fei, Wei Wujie, Li Zihui, Liu Li, Deng J |
| Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience. ESMO open 2022 6 7 (3): 100506. Boccaccino A, Borelli B, Intini R, Antista M, Bensi M, Rossini D, Passardi A, Tamberi S, Giampieri R, Antonuzzo L, Noto L, Roviello G, Zichi C, Salati M, Puccini A, Noto C, Parisi A, Rihawi K, Persano M, Crespi V, Libertini M, Giordano M, Moretto R, Lonardi S, Cremolini |
| FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research 2022 9 29 (3): 508-512. Duke Elizabeth S, Stapleford Liza, Drezner Nicole, Amatya Anup K, Mishra-Kalyani Pallavi S, Shen Yuan-Li, Maxfield Kimberly, Zirkelbach Jeanne Fourie, Bi Youwei, Liu Jiang, Zhang Xinyuan, Wang Hezhen, Yang Yuching, Zheng Nan, Reece Kelie, Wearne Emily, Glen Jacqueline J, Ojofeitimi Idara, Scepura Barbara, Nair Abhilasha, Bikkavilli Rama Kamesh, Ghosh Soma, Philip Reena, Pazdur Richard, Beaver Julia A, Singh Harpreet, Donoghue Mart |
| Osimertinib plus selumetinib in EGFR-mutated, non-small cell lung cancer after progression on EGFR-TKIs: A Phase 1b, open-label, multicenter trial (TATTON Part B). Clinical cancer research : an official journal of the American Association for Cancer Research 2022 5 . Yang James Chih-Hsin, Ohe Yuichiro, Chiu Chao-Hua, Ou Xiaoling, Cantarini Mireille, Jänne Pasi A, Hartmaier Ryan J, Ahn Myung |
| Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial. JAMA oncology 2021 Oct e214761. Zhou Caicun, Ramalingam Suresh S, Kim Tae Min, Kim Sang-We, Yang James Chih-Hsin, Riely Gregory J, Mekhail Tarek, Nguyen Danny, Garcia Campelo Maria R, Felip Enriqueta, Vincent Sylvie, Jin Shu, Griffin Celina, Bunn Veronica, Lin Jianchang, Lin Huamao M, Mehta Minal, Jänne Pasi |
| Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. JAMA oncology 2021 Aug . Martinelli Erika, Martini Giulia, Famiglietti Vincenzo, Troiani Teresa, Napolitano Stefania, Pietrantonio Filippo, Ciardiello Davide, Terminiello Marinella, Borrelli Carola, Vitiello Pietro Paolo, De Braud Filippo, Morano Federica, Avallone Antonio, Normanno Nicola, Nappi Anna, Maiello Evaristo, Latiano Tiziana, Falcone Alfredo, Cremolini Chiara, Rossini Daniele, Santabarbara Giuseppe, Pinto Carmine, Santini Daniele, Cardone Claudia, Zanaletti Nicoletta, Di Liello Alessandra, Renato Daniela, Esposito Lucia, Marrone Francesca, Ciardiello Fortuna |
| Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer. Clinical colorectal cancer 2021 Jul . Alshammari Kanan, Aung Kyaw L, Zhang Tong, Razak Albiruni R A, Serra Stefano, Stockley Tracy, Wang Lisa, Nguyen Jessica, Spreafico Anna, Hansen Aaron R, Zwir Dave, Siu Lillian L, Bedard Philippe |
| A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer. Cancer chemotherapy and pharmacology 2021 11 89 (1): 105-115. Padda Sukhmani K, Reckamp Karen L, Koczywas Marianna, Neal Joel W, Kawashima Jun, Kong Shengchun, Huang Daniel B, Kowalski Mark, Wakelee Heather |
| A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer. Cancer management and research 2021 12 13 8695-8705. Igawa Satoshi, Kasajima Masashi, Ono Taihei, Ozawa Takahiro, Kakegawa Mikiko, Kusuhara Seiichiro, Sato Takashi, Nakahara Yoshiro, Fukui Tomoya, Yokoba Masanori, Kubota Masaru, Mitsufuji Hisashi, Sasaki Jiichiro, Naoki Katsuhi |
| A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632. Lung cancer (Amsterdam, Netherlands) 2021 9 161 49-54. Noro Rintaro, Igawa Satoshi, Bessho Akihiro, Hirose Takashi, Shimokawa Tsuneo, Nakashima Masanao, Minato Koichi, Seki Nobuhiko, Tokito Takaaki, Harada Toshiyuki, Sasada Shinji, Miyamoto Shingo, Tanaka Yosuke, Furuya Naoki, Kaburagi Takayuki, Hayashi Hideki, Iihara Hirotoshi, Okamoto Hiroaki, Kubota Kao |
| Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies. Frontiers in oncology 2021 11 709877. Passaro Antonio, de Marinis Filippo, Tu Hai-Yan, Laktionov Konstantin K, Feng Jifeng, Poltoratskiy Artem, Zhao Jun, Tan Eng Huat, Gottfried Maya, Lee Victor, Kowalski Dariusz, Yang Cheng Ta, Srinivasa B J, Clementi Laura, Jalikop Tejaswini, Huang Dennis Chin Lun, Cseh Agnieszka, Park Keunchil, Wu Yi-Lo |
| Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations. Medicina (Kaunas, Lithuania) 2021 9 57 (9): . Yamada Yutaka, Imai Hisao, Sugiyama Tomohide, Minemura Hiroyuki, Kanazawa Kenya, Kasai Takashi, Minato Koichi, Kaira Kyoichi, Kaburagi Takayu |
| Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence. Journal of oncology 2021 12 2021 8736288. Zhang Lemeng, Luo Yongzhong, Chen Jianhua, Cheng Tianli, Yang Hua, Pan Changqie, Li Haitao, Jiang Zh |
| First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study. Investigational new drugs 2021 11 40 (2): 430-437. Igawa Satoshi, Fukui Tomoya, Kasajima Masashi, Ono Taihei, Ozawa Takahiro, Kakegawa Mikiko, Kusuhara Seiichiro, Sato Takashi, Nakahara Yoshiro, Hisashi Mitsufuji, Sasaki Jiichiro, Naoki Katsuhi |
| Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors. JTO clinical and research reports 2021 9 2 (9): 100206. Park Keunchil, Tan Daniel Shao Weng, Su Wu-Chou, Cho Byoung Chul, Kim Sang-We, Lee Ki Hyeong, Wang Chin-Chou, Seto Takashi, Huang Dennis Chin-Lun, Jung Helen Hayoun, Hsu Ming-Chi, Bogenrieder Thomas, Lin Chia-C |
| RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability. Drug safety 2021 12 45 (1): 45-64. Nadal Ernest, Horinouchi Hidehito, Shih Jin-Yuan, Nakagawa Kazuhiko, Reck Martin, Garon Edward B, Wei Yu-Feng, Kollmeier Jens, Frimodt-Moller Bente, Barrett Emily, Lipkovich Olga, Visseren-Grul Carla, Novello Silv |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 20, 2023
- Content source: